Shattuck Expands SL-325 to Phase 2 HS Trial, Cash Runway Into 2029

What happened

Shattuck Labs announced plans to advance SL-325 into a Phase 2 trial in hidradenitis suppurativa (HS), with the RECEPTIVE-HS1 study expected to initiate in 2026 and 16-week data in H1 2028, marking a second indication beyond IBD. The company also named Shoba Ravichandran, M.D., as SVP Clinical Development to lead the HS program, while reiterating cash runway into 2029. The announcement provides no new clinical data for SL-325, and the HS trial is still in planning stages, with timelines extending nearly two years to initial readout. The move appears aimed at broadening the DR3 antagonist's potential market, but competitive TL1A/DR3 dynamics and unresolved listing compliance remain key overhangs. Investors should treat the news as a modest de-risking of pipeline breadth, not a proof of clinical efficacy.

Implication

The announcement adds a second inflammatory indication to SL-325's pipeline, potentially broadening its addressable market if the DR3 mechanism works across diseases. However, the HS trial will not start until 2026, and data readouts are not expected until 2028, meaning the stock may remain range-bound absent other catalysts. The appointment of an experienced clinical development lead is a plus, but execution risk persists given the company's pre-revenue status and dependence on future financing. Cash runway into 2029 provides some cushion, but dilution risk and Nasdaq listing compliance remain concerns. Overall, the news does not alter the fundamental investment thesis; we await clinical proof-of-concept data before considering a more constructive stance.

Thesis delta

The thesis is largely unchanged, as the announcement adds a second Phase 2 indication but no clinical data. The extension of cash runway into 2029 modestly de-risks liquidity, but the core risk remains clinical validation of SL-325 in any indication. We maintain our WAIT judgment pending initial efficacy signals.